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A ntibiotic prophylaxis prior to invasive surgical procedures is used to decrease the incidence of 
surgical site infections (SSIs) [1].  This approach can 
induce asepsis at the operative site,  thereby preventing 
contamination by bacterial content and ultimately SSIs 
[1, 2].
In the context of neurological medicine,  muscle 
biopsy is an important but invasive procedure performed 
to obtain information on,  for example,  muscle fiber 
degeneration or the presence of infiltrating inflammatory 
cells,  facilitating a direct understanding of the patient’s 
clinical state and a more definitive diagnosis [3, 4].  
Following muscle biopsy,  oral antibiotics may be pre-
scribed to prevent the occurrence of SSIs,  and to date 
we have not experienced SSI in this clinical setting.  
However,  there are no guidelines and no evidence 
regarding the use of antibiotic prophylaxis or whether it 
is necessary in patients undergoing a muscle biopsy; it 
is thus unclear whether this treatment strategy is appro-
priate.  Moreover,  previous studies reported that antibi-
otic prophylaxis prior to surgery or less-invasive exam-
inations did not decrease the incidence of SSIs [5-7],  and 
antibiotic prophylaxis has been questioned in some cases.  
According to the Japanese clinical practice guidelines for 
antimicrobial prophylaxis in surgery,  when performing 
soft tissue surgery (muscle,  tendon,  and peripheral 
nerve),  the administration of cefazolin within 24 h is 
recommended [7].  However,  the guidelines include a 
proviso that consensus was not achieved regarding anti-
biotic prophylaxis in patients at low risk of SSI or in 
those undergoing short-duration procedures [7].  The 
duration of a muscle biopsy is typically < 1 h,  and this 
procedure is less invasive compared to other common 
surgeries such as orthopedic procedures.  Antibiotic 
prophylaxis may be useful for patients with diabetes who 
are at high risk of SSIs [8],  patients with infected wounds 
[8],  patients undergoing surgical procedures with longer 
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durations [8],  patients with a body mass index ≥25 kg/m2 
[9],  and patients who are immunocompromised [10].
We therefore plan to evaluate the incidence of SSI in 
patients who are immunocompetent,  at low risk of SSI,  
and undergoing a muscle biopsy with or without antibi-
otic prophylaxis.  If the incidences of SSI in the patients 
with and without antibiotic prophylaxis are comparable,  
it is possible that the superfluous use of antibiotic pro-
phylaxis can be reduced,  thereby decreasing the oppor-
tunity for bacteria to acquire antibiotic resistance.
Study Design
This study is a phase 2,  single-center,  open-labeled,  
prospective randomized trial to investigate whether the 
use of antibiotic prophylaxis during a muscle biopsy in 
low-risk immunocompetent patients is required.  An 
overview of the study design is shown in Fig.1.  This trial 
is being conducted at Kumamoto University Hospital.
Ethical Considerations
The study has been approved by the Institutional 
Review Board of Kumamoto University (permit no. 2384).  
Written informed consent will be obtained from all 
patients prior to their participation,  and all procedures 
will be carried out with the adequate understanding of 
each patient and in accordance with the Declaration of 
Helsinki.  This trial is registered with the University 
Hospital Medical Information Network Individual 
Clinical Trials Registry (UMIN 000034535).
Endpoints
The primary endpoint is the rate of SSIs during an 
observation period defined as the time point of the muscle 
biopsy to the time point of the suture removal at the site.  
The incidence of SSI will be judged by either the patient’s 
attending physician or the physician performing the 
muscle biopsy.  SSI is defined as the existence of pus or 
serous fluid containing pathogenic organisms.
Secondary endpoints include the background charac- 
teristics of patients in the 2 groups (with/without antibi-
otic prophylaxis); adverse events associated with anti-
biotic treatment; wound scoring [11] at the muscle 
biopsy region; the relationship between the number of 
days until suture removal and treatment with or without 
antibiotics; the relationship between body temperature 
and treatment with or without antibiotics; and the rela-
tionship between treatment with/without antibiotics and 
longitudinal changes in the following laboratory blood 
parameters: red blood cells (RBC),  white blood cells 
(WBC) and subsets (neutrophils,  lymphocytes,  mono-
cytes,  eosinophils,  and basophils),  hemoglobin (Hb),  
platelets (PLT),  blood urea nitrogen (BUN),  creatinine 
(Crea),  total protein (TP),  albumin (Alb),  creatine 
kinase (CK),  aspartate transaminase (AST),  alanine 
transaminase (ALT),  and C-reactive protein (CRP).
In addition,  the characteristics of the patients with 
SSI will be examined.  Wound scoring with a maximum 
of 100 points will be used as follows: prolongation of 
admission to treat an SSI (2 points per day and maximum 
20 points),  use of wound dressing (1 point per day and 
maximum 10 points),  existence of pus (10 points) and 
serous fluid (10 points),  presence of pathogens (10 points),  
incidence of cellulitis (moderate or severe: 10 points;  
mild: 5 points),  use of antibiotics to treat SSI infection 
(10 points) and wound dehiscence (10 points),  and 
need for surgical drainage (10 points).
A subgroup analysis will be performed to validate 
the relationship between longitudinal changes in labo-
ratory blood data and the disease type (inflammatory 
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myopathies,  inclusion body myositis,  and other muscle 
diseases),  the muscle biopsy region,  the duration (min) 
of the muscle biopsy procedure,  and the manual muscle 
testing (MMT) value of the muscle region where the 
muscle biopsy is performed,  as well as the relationship 
between the duration of the muscle biopsy procedure,  
the disease type,  the muscle biopsy region,  and the 
MMT value.
Eligibility Criteria
The inclusion and exclusion criteria are listed in 
Table 1.  Eligible patients will be enrolled from 
September 2018 to March 2022.
Randomization
Information on eligible patients who have received 
verbal and written information on the study and provided 
written informed consent will be registered in the 
HOPE eACReSS system (Fujitsu,  Japan) at Kumamoto 
University Hospital.  Patients will be randomly assigned 
to an antibiotic prophylaxis group or a control group 
within the HOPE eACReSS system using a stratified 
permuted block method.  Patients will be stratified by 
sex,  and no blinding will be applied.
Treatment Methods
Intervention. For the evaluation of primary or 
secondary endpoints,  all enrolled patients in both groups 
will be monitored daily during the hospital stay.  On the 
day of the muscle biopsy procedure,  patients in the 
antibiotic prophylaxis group will receive a single intra-
venous dose of 1 g cefazolin,  administered continuously 
during the 30 min prior to the start of the procedure.  
After completion of the muscle biopsy procedure,  the 
wound will be covered with an OpsiteTM Post-Op Visible 
dressing,  and the presence or absence of SSI without 
disinfection will be confirmed daily.  In the absence of 
any complications,  the dressing will be removed 5 days 
after the muscle biopsy,  and sutures will be removed at 
7-10 days after the procedure.
Vital signs will be recorded and a blood sample taken 
after informed consent is obtained from eligible patients.  
The disease type and muscle biopsy region will be 
recorded 1 day prior to the muscle biopsy procedure.  
Upon completion of the procedure,  the duration of the 
muscle biopsy procedure,  the MMT value,  and the use 
of analgesics such as non-steroidal anti-inflammatory 
drugs (NSAIDs) to inhibit muscle biopsy-associated pain 
will be recorded.  Vital signs and analgesic use will be 
recorded and blood sampling will be performed at days 
1 and 3 after the procedure and at the time point of 
suture removal.  All patients will be followed until suture 
removal,  at which point the wound score and the num-
ber of days from the muscle biopsy to the suture removal 
will be recorded.  The incidence of SSI infection will be 
documented throughout the observation period.
Adverse events. Adverse events related to cefazolin 
use,  including allergy or anaphylactic shock,  blood 
disorders such as granulocytopenia,  liver failure,  kid-
ney failure,  pseudomembranous colitis,  skin disorders 
such as Stevens-Johnson syndrome,  and interstitial lung 
disease will be monitored during the hospital stay.  
Although SSIs are also considered adverse events,  the 
incidence of SSI will be recorded as the primary end-
point.
Statistical Considerations
Sample size. In studies using retrospective data,  
the incidence probability of SSI has been considered to 
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(11) Planned treatment with an immunosuppressive agent immedi-
ately after muscle biopsy
(12) Presence of a skin lesion at the planned site of muscle 
biopsy 
(13) Patients who are judged unsuitable for participation in this 
trial by the attending physician
be very low [5, 6].  Particularly,  in the case of minimally 
invasive operations such as inguinal hernia repair,  the 
non-incident rate of SSI was > 0.99 with or without anti-
biotic prophylaxis [6].  Moreover,  we typically do not 
observe SSIs in patients undergoing a muscle biopsy at 
our hospital when oral antibiotics are administered after 
the muscle biopsy.  Therefore,  we estimated the thresh-
old probability of not developing SSI in the group with-
out antibiotic prophylaxis as 0.990-0.995,  which was 
described as π.  The probability of developing SSI was 
thus 1-(π)n,  so we calculated that 6-11 patients would 
be needed in each group (probability < 0.05).  Finally,  
we selected 11 patients as the size of each group for the 
analyses of secondary endpoints,  and we plan to include 
24 patients in total to allow for potential exclusions or 
withdrawals.
Statistical analysis. For the primary endpoint,  
Fisher’s exact test will be used for comparisons between 
the 2 groups because accurate comparative verification 
is expected to be difficult,  given that the sample size was 
estimated independently for the 2 groups.  For the sec-
ondary endpoints,  continuous data will be expressed as 
medians and interquartile ranges.  Categorical variables 
will be presented as percentages.  To ascertain a normal 
distribution of variables,  Shapiro-Wilk’s test will be 
performed.  For a univariate analysis,  a Wilcoxon rank 
sum test will be used for continuous variables and 
Fisher’s exact test will be used for categorical variables.  
A linear mixed model will be used to examine the 
effects of antibiotic prophylaxis on the time course of 
laboratory blood data at days 1 and 3 after each muscle 
biopsy and at suture removal compared with the base-
line blood data prior to the procedure.  Adverse events 
associated with antibiotic use will be graded and cate-
gorized according to the Common Terminology 
Criteria for Adverse Events (ver. 5.0).
In the subgroup analysis,  the disease type,  muscle 
biopsy region,  duration of the muscle biopsy procedure,  
and MMT value will be analyzed for each group,  and 
changes in laboratory blood data will be used in linear 
mixed models.  To validate the relationship between the 
duration of the muscle biopsy procedure and the disease 
type or muscle biopsy region or MMT value,  a two-way 
analysis of variance or multivariate analysis will be per-
formed.  The data analyses will be performed using R 
ver. 3.3.2 (The R Foundation for Statistical Computing,  
Vienna,  Austria) and SAS ver. 9.4 (SAS Institute,  Cary,  
NC,  USA) with the level of statistical significance set at 
p < 0.05.
Limitations. It is possible that there is an inci-
dental risk of SSI other than those considered in our 
exclusion criteria (i.e.,  hepatic failure or poor nutri-
tional status).  In addition,  although we narrowed the 
target age in the inclusion criteria,  age is an obvious 
confounding factor; when we perform the subgroup 
analysis,  we will therefore consider the risk factors.
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